logo-loader
BlueJay Mining PLC

Bluejay Mining submits prefeasibility study for Dundas project

“The conclusions drawn from this study indicate positive economic outcomes and low environmental impact, with strong social benefits."

Bluejay Mining's Dundas project
It is based on a yearly production of 440,000 tonnes of ilmenite concentrate

Bluejay Mining Plc (LON:JAY) told investors that it has now submitted the prefeasibility study for the Dundas ilmenite project in Greenland.

The study has been submitted to the mineral licence and safety authority (MLSA) of the Government of Greenland, marking the completion of the final necessary item to facilitate an exploitation application.

READ: Bluejay Mining still well-cashed up for further work on Dundas

"The lodgement of this PFS marks the completion of the final module necessary to make an exploitation application and we expect to make this as soon as regulatory comments have been responded to,” said Roderick McIllree, Bluejay's chief executive.

“We are delighted to have completed and submitted this detailed document to the regulators. The conclusions drawn from this study indicate positive economic outcomes and low environmental impact, with strong social benefits.

"We will update the market in due course with details of the PFS and its outcomes," he added.

Quick facts: BlueJay Mining PLC

Price: £0.08

Market: AIM
Market Cap: £64.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BlueJay Mining PLC named herein, including the promotion by the Company of BlueJay Mining PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Allergy Therapeutics receives multi-million-dollar settlement

Top stories from the Proactive Investors UK newsroom. Allergy Therapeutics (LON:AGY) has accepted US$7.6mln in settlement of a dispute over the procedures used for a US grass pollen vaccine trial. Allergy blamed the inconclusive trial results on the way the study was carried...

on 27/6/19

2 min read